Variants of the GSTO1 gene affect the metabolism of drugs such as cisplatin, carboplatin, and arsenic-based treatments by altering enzyme activity. This impacts the detoxification of drug metabolites and reactive oxygen species, influencing both the effectiveness of the drugs and the severity of side effects associated with their use.